Long-Term Oncologic Outcome of Breast Cancer in Southern Iran: A Retrospective Cohort Study.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Nov 2022
Historique:
received: 28 06 2022
entrez: 29 11 2022
pubmed: 30 11 2022
medline: 1 12 2022
Statut: epublish

Résumé

Breast cancer remains the most frequent and lethal cancer among women worldwide. This study aimed to investigate the characteristics, prognostic factors and outcome of breast cancer patient treated and followed-up in Shiraz, southern Iran from 2000 to 2005. In this retrospective study, 1,024 patients with breast cancer who were treated in Namazi hospital of Shiraz University of Medical Sciences between 2000 and 2005 were included. Survival analysis was performed to determine potential factors influencing disease free-and overall survival in these patients. Median age of the patients at diagnosis was 47 (range 19-83) years. Median follow-up for surviving patients was 68 months. The majority of patients presented at stage II (42%) and stage III (41%). Additionally, most (61%) patients had positive axillary node. The 5-, 10- and 15-year overall survival rates were 83.8%, 61.5% and 56.6% respectively. On multivariate analysis for overall survival, histologic type, Tumor stage, node stage, disease stage, M stage, hormone receptor status, adjuvant radiotherapy, and chemotherapy regimen remained independent prognostic factor for overall survival. in this study, the poor long-term oncologic outcome of the patients with breast cancer may be due to the higher rate of locally advanced disease; as well as the lack of modern systemic therapies in the study period.

Identifiants

pubmed: 36444601
doi: 10.31557/APJCP.2022.23.11.3877
pmc: PMC9930976
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3877-3884

Références

Lancet Oncol. 2019 Mar;20(3):361-370
pubmed: 30709633
Clin Exp Metastasis. 2017 Jan;34(1):93-101
pubmed: 27718076
PeerJ. 2019 Jul 04;7:e7252
pubmed: 31309004
N Engl J Med. 2004 Jul 29;351(5):427-37
pubmed: 15282350
Cancer. 2005 May 1;103(9):1898-905
pubmed: 15800894
Horm Mol Biol Clin Investig. 2020 Oct 21;41(4):
pubmed: 33079703
Iran J Public Health. 2020 Feb;49(2):341-350
pubmed: 32461942
BMJ. 2000 Sep 9;321(7261):624-8
pubmed: 10977847
Sci Rep. 2020 Dec 8;10(1):21477
pubmed: 33293634
Clin Breast Cancer. 2018 Jun;18(3):239-245
pubmed: 29033239
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Cancer Manag Res. 2018 Sep 27;10:4005-4018
pubmed: 30310322
Breast J. 2021 Aug;27(8):657-663
pubmed: 34120364
BMJ. 2015 Oct 06;351:h4901
pubmed: 26442924
Biosci Rep. 2019 Jun 4;39(6):
pubmed: 31113872
Radiother Oncol. 2007 Mar;82(3):272-80
pubmed: 17287037
Prz Menopauzalny. 2015 Sep;14(3):196-202
pubmed: 26528110
Iran J Public Health. 2018 Mar;47(3):309-316
pubmed: 29845017
BMC Cancer. 2009 Jun 05;9:168
pubmed: 19497131
Asian Pac J Cancer Prev. 2021 Oct 01;22(10):3081-3092
pubmed: 34710982
Breast Cancer Res Treat. 2008 Feb;107(3):309-30
pubmed: 17377838
Sci Rep. 2017 Sep 11;7(1):11058
pubmed: 28894168
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Ecancermedicalscience. 2017 Jan 24;11:715
pubmed: 28194227
Ann Oncol. 2004 Nov;15(11):1640-4
pubmed: 15520065
Iran J Public Health. 2021 Jan;50(1):35-45
pubmed: 34178762
Br J Cancer. 2019 Feb;120(4):398-403
pubmed: 30723304
Cancer. 2015 Jan 15;121(2):269-75
pubmed: 25224030
J Natl Cancer Inst. 2010 Mar 17;102(6):410-25
pubmed: 20190185
Asian Pac J Cancer Prev. ;17(10):4615-4621
pubmed: 27892673
PLoS One. 2019 Jan 4;14(1):e0208701
pubmed: 30608935

Auteurs

Ali Omidvari (A)

Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Alireza Salehi (A)

Department of MPH, School of Medicine Shiraz University of Medical Sciences Shiraz, Iran.

Mahsa Sepahvand (M)

Department of MPH, School of Medicine Shiraz University of Medical Sciences Shiraz, Iran.

Shapour Omidvari (S)

Department of MPH, School of Medicine Shiraz University of Medical Sciences Shiraz, Iran.

Mohammad Mohammadianpanah (M)

Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH